Biodexa Registers 127.8M Shares for Resale, Unleashing a Massive Dilution Overhang from July Offerings
BDRX sits 41% above its 52-week low of $1.02.
Summary
Biodexa registers 127.8 million ordinary shares for resale by Armistice Capital, representing warrants from the July 1 offering. If fully exercised, outstanding shares would surge 248% to 179.2 million, creating a massive dilution overhang on a company with a $653,000 market cap.
Key Events · Financing and Capital Events · BDRX
-
127.8M Share Resale Registration
The F-1 registers 127,754,750 ordinary shares (2,555,095 ADSs) for resale by Armistice Capital, covering shares underlying pre-funded warrants and Series M, N, and O warrants from the July 1, 2026 offerings.
-
Massive Potential Dilution
If all warrants are exercised, total outstanding ordinary shares would increase from 51.5 million to 179.2 million — a 248% increase. The selling shareholder would still own 26.4% post-resale.
-
Overhang on Micro-Cap Stock
The registered shares represent a multiple of the company's $652,613 market cap. The registration makes this overhang immediately tradable, creating severe selling pressure.
-
Reverse Split and Shareholder Approval
The registration follows a 1-for-10,000 reverse stock split effective July 30, 2026, and shareholder approval on July 29, 2026, which authorized the board to issue up to £25 million in shares.
Analysis · BDRX · Life Sciences
This F-1 registers 127.8 million ordinary shares (2.56 million ADSs) for resale by Armistice Capital, the sole investor in Biodexa's July 1 multi-part offering. The shares underlie pre-funded warrants and Series M, N, and O warrants issued in that $3.54 million raise. If all warrants are exercised, total outstanding shares would balloon from 51.5 million to 179.2 million — a 248% increase. Even after the resale, the selling shareholder would still hold 26.4% of the company. The registration makes this massive overhang immediately tradable, creating severe selling pressure on a micro-cap stock already battered by a 1-for-10,000 reverse split executed yesterday. While the offering was priced at $2.85 per ADS, a premium to the current $1.44, the sheer volume of shares now eligible for sale dwarfs the company's $653,000 market cap. This is a textbook toxic financing overhang: the company got $3.5 million in cash, but existing shareholders face potential dilution that could crush the stock.
How filings like this one have moved
In the 30 days to Sep 13, 2026, 42% of the 419 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.47%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BDRX was trading at $1.44 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $652.6K. The 52-week trading range was $1.02 to $59.40. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.